奥希替尼对比标准EGFR-TKI在初治EGFR突变晚期非小细胞肺癌患者中的中枢神经系统疗效
FLAURA III期研究预设亚组分析,556例初治EGFR突变晚期NSCLC患者随机接受奥希替尼或标准EGFR-TKI(吉非替尼或厄洛替尼)。CNS客观缓解率在可测量CNS病灶患者中分别为91%和68%。结论提示奥希替尼对CNS病灶有效,可降低CNS进展风险。
要点
- 可测量CNS病灶患者CNS客观缓解率:奥希替尼91% vs 标准EGFR-TKI 68%。
- 奥希替尼组CNS进展事件概率 consistently 更低。
核心结论
- 奥希替尼对初治EGFR突变晚期NSCLC患者的CNS病灶具有疗效。
- 结果提示奥希替尼较标准EGFR-TKI可降低CNS进展风险。
研究设计与样本
- FLAURA III期研究预设亚组分析,纳入556例初治EGFR突变晚期NSCLC患者,随机接受奥希替尼或标准EGFR-TKI(吉非替尼或厄洛替尼)。
- 基线脑扫描非强制,仅临床需要时进行;纳入无症状或稳定CNS转移患者。
- CNS可评估集为基线脑扫描存在可测量和/或不可测量CNS病灶者,由盲法独立中心神经影像学评估。
主要发现
- 200例有基线脑扫描患者中,128例存在可测量和/或不可测量CNS病灶(奥希替尼组61例,标准EGFR-TKI组67例),其中41例有≥1个可测量CNS病灶(奥希替尼组22例,标准EGFR-TKI组19例)。
临床怎么用
- 对于初治EGFR突变晚期NSCLC伴CNS转移患者,奥希替尼可作为优先考虑以降低CNS进展风险。
- 基线存在可测量和/或不可测量CNS病灶者可从奥希替尼治疗中获得更高的CNS缓解率和更长的CNS无进展生存。
局限性
- 脑扫描非强制,仅200例有基线脑扫描,CNS可评估集样本量有限。
- CNS无进展生存分析为预设亚组分析,名义统计学显著性需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.
引用
- Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 30153097. doi:10.1200/JCO.2018.78.3118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。